Key result
Immature platelets show consistently higher reactivity than mature platelets in STEMI patients.
Why the study?
Reduced effect of antiplatelet therapy has been reported in STEMI patients, which could partly be explained by an increase of highly reactive immature platelets.
Does the reactivity of immature platelets change following acute STEMI despite standard antiplatelet therapy?
Observational (n=44)
Does the reactivity of immature platelets change following acute STEMI despite standard antiplatelet therapy?
Immature platelets remain highly reactive in STEMI patients despite standard loading and maintenance antiplatelet therapy, potentially explaining reduced antiplatelet efficacy in this population.
Answers are grounded in this paper and cite their sources.
Immature platelet hyperreactivity persists post-STEMI on standard therapy; hypothesis-generating for targeted interventions before practice change.
Abstract Background Reduced effect of antiplatelet therapy has been reported in patients with ST-segment elevation myocardial infarction (STEMI). This could partly be explained by an increase of highly reactive immature platelets. Objectives To investigate changes in platelet maturity and reactivity after acute STEMI. Methods Patients diagnosed with STEMI, admitted for primary percutaneous coronary intervention, and treated according to international guidelines, were included. Blood samples were obtained within 24 hours after admission and at 2- to 3-months follow-up. Platelet maturity and reactivity using multicolor flow cytometry with SYTO-13 to categorize platelet maturity, whole blood platelet aggregation, serum thromboxane B2 levels, and standard immature platelet markers (eg, immature platelet count and fraction, and mean platelet volume) were measured. Results A total of 44 STEMI patients were included. The reactivity of immature platelets was consistently higher at baseline and at follow-up when compared to the entire platelet population and the mature platelet population (all P values < .05). The expression of CD63 (a dense granule marker) in immature platelets was consistently high compared to the entire platelet population and the mature platelet population and did not change from baseline to follow-up (P values > .24). Additionally, a positive significant correlation was found between standard immature platelet markers and the expression of CD63 on platelets both at baseline and follow-up (rho ranging from 0.32 to 0.62, all P values < .05). Conclusion Immature platelets represent a highly reactive platelet subpopulation crucial for the overall platelet reactivity, partly due to a high expression of dense granules. Despite treatment with loading and maintenance doses of antiplatelet therapy, the reactivity of immature platelets remained high in STEMI patients.
No takes yet. Share an insight, caveat, or question.
Pedersen et al. (2024) conducted an observational in ST-segment elevation myocardial infarction (STEMI) (n=44). Antiplatelet therapy was evaluated on Reactivity of immature platelets compared to the entire and mature platelet populations (p=<.05). Immature platelets showed consistently higher reactivity compared to the entire and mature platelet populations in STEMI patients at baseline and 2-3 months follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: